
==== Front
Br J Surg
Br J Surg
bjs
The British Journal of Surgery
0007-1323
1365-2168
Oxford University Press UK

10.1093/bjs/znae240
znae240
Original Article
AcademicSubjects/MED00910
Bjs/1
Bjs/8
Timing and type of breast reconstruction in SweBRO 3: long-term outcomes
Gümüscü Rojda Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

https://orcid.org/0000-0002-0130-7296
Wärnberg Fredrik Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Department of Surgery, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden

https://orcid.org/0000-0001-9518-0902
de Boniface Jana Department of Surgery, Capio St. Göran’s Hospital, Stockholm, Sweden
Department of Medicine and Surgery, Karolinska Intitutet, Stockholm, Sweden

https://orcid.org/0000-0002-7516-9543
Sund Malin Department of Surgery and Perioperative Sciences, Umeå University, Umeå, Sweden
Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Åhsberg Kristina Department of Surgery, Halland Hospital, Halmstad, Sweden
Department of Clinical Sciences, Lund University, Lund, Sweden

Hansson Emma Department of Plastic Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Region Västra Götaland, Sahlgrenska University Hospital, Department of Plastic and Reconstructive Surgery, Gothenburg, Sweden

Folkvaljon Folke Sveastat AB, Kungsbacka, Sweden

https://orcid.org/0000-0002-1357-9125
Unukovych Dmytro Department of Plastic and Craniofacial Surgery, Karolinska University Hospital, Stockholm, Sweden

Mani Maria Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Department of Plastic and Reconstructive Surgery, Uppsala University Hospital, Uppsala, Sweden

Correspondence to: Rojda Gümüscü, MD, PhD, Department of Plastic and Reconstructive Surgery, Uppsala University Hospital, 751 85 Uppsala, Sweden (e-mail: rojda.gumuscu@surgsci.uu.se)
9 2024
24 9 2024
24 9 2024
111 9 znae24023 5 2024
18 8 2024
23 8 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.
2024
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Breast reconstruction after mastectomy helps women with breast cancer feel better about their bodies and lives. There is debate about the best time and type of reconstruction (immediate versus delayed, and using own tissue versus implants). Long-term studies are rare.

Aim

This study looked at long-term results of different breast reconstruction methods and timings in Swedish women who had mastectomies in 2000, 2005 or 2010. It focused on how satisfied the women were with their surgeries and their quality of life.

Method

The study included 5853 women from the Swedish National Breast Cancer Registry who had mastectomies in 2000, 2005 or 2010. Of these, 2904 women answered the survey, and 895 had breast reconstruction. Satisfaction and quality of life were measured using two surveys: EORTC QLQ-BRECON23 and BREAST-Q.

Results

Of the women who answered the survey, 895 (31%) had breast reconstruction. Of these, 176 (20%) had immediate reconstruction, and 719 (80%) had delayed reconstruction; 58% had implant-based reconstructions, 31% had reconstructions using their own tissue, 2% had both types and 9% did not report the type of reconstruction. There were no major differences in satisfaction between immediate and delayed reconstruction. Women who used their own tissue were more satisfied with their results and breast appearance than those with implants.

Conclusion

Autologous reconstruction leads to better satisfaction and outcomes than implants. The timing of reconstruction (immediate versus delayed) was less of an influence on quality of life.

Breast reconstruction following mastectomy plays a crucial role in restoring body image and quality of life for women with breast cancer. The optimal timing and reconstruction type remain subjects of debate, and population-based long-term studies on this topic are lacking. This national long-term follow-up survey highlights better well-being and quality of life among women with autologous reconstructions compared to implant-based reconstructions.

ALF 10.13039/501100001034 The Swedish Breast Cancer Association
==== Body
pmcIntroduction

Breast cancer remains a significant global health burden affecting millions of women, and its management sometimes involves mastectomy, a procedure that can significantly impact physical and emotional well-being1,2. In the pursuit of restoring physical appearance and enhancing the health-related quality of life (HRQoL), breast reconstruction has emerged as a vital component of the treatment process2.

The timing and method of breast reconstruction can vary, with two primary approaches commonly used; that is, immediate versus delayed reconstruction and autologous versus implant-based reconstruction. The choice of reconstruction timing and method depends on several factors, including the patient’s overall health, cancer treatment plan, body type and the personal preferences of the patient and surgeon. Such preferences, however, vary considerably and the scientific evidence for when and how to reconstruct in order to obtain the best long-term results is low.

Immediate breast reconstruction (IBR) is performed at the same time as the mastectomy. This approach has the advantage of never living without a breast, which can help alleviate the emotional impact of a breast loss. Delayed reconstruction (DBR) is performed months or years after the mastectomy. It allows the patient to recover from the necessary treatments and ensure cancer control before undergoing reconstruction.

A previous study has shown no significant differences in patient satisfaction, psychosocial, sexual or physical well-being between IBR and DBR, despite being based on a prospective multicentre study with a response rate exceeding 91% and a 2-year follow-up period3.

A review of nine studies showed that IBR had a positive impact on patient well-being although the findings are constrained by variables such as small study sizes and inconsistent methodologies. Psychological support was suggested to be crucial and should be available for all breast cancer surgery patients due to the profound emotional effects4. However, there was an advantage of choosing IBR with better psychological well-being.

Other findings include improved body image in IBR patients according to Harcourt and Rumsey5 and better psychosocial well- being in IBR patients reported by Al Ghazal et al.3. Harcourt and Rumsey5, however, suggested that the surgical procedure itself, regardless of reconstruction, did not significantly impact body image.

Implant-based reconstruction involves the use of breast implants or expandable implants to recreate the breast mound. Autologous reconstruction, also known as flap reconstruction, employs a woman's own tissue to reconstruct the breast. Depending on patient anatomy, the tissue can usually be taken from the abdomen (for example, deep inferior epigastric perforator, DIEP flap), back (for example, latissimus dorsi, LD flap), or thigh/gluteal area (for example, profunda artery perforator, PAP flap). These methods generally lead to a breast that appears and feels more natural. In some cases, a combination of both implant and autologous tissue is used.

Although the existing literature highlights enhanced long-term durability, decreased rates of reconstructive failure and lower occurrences of surgical site infections associated with autologous tissue6, implant-based reconstruction offers a shorter recovery period and avoids donor-site morbidity6–9.

Patient-reported outcome measures (PROMs)8,9 have become an independent parameter for treatment outcomes alongside clinical measurements10,11. There are few systematic reviews analysing PROMs in autologous versus implant-based reconstruction, hindering the determination of a patient-preferred technique. The largest systematic review by Phan et al.12 including 13 published articles showed that the autologous group, assessed by the BREAST-Q, demonstrated higher satisfaction levels in both breast-related and psychosocial well-being compared to implant-based reconstruction. There were less pronounced differences in physical well-being, and the least significant variance was observed in sexual well-being. Similar trends were identified with another validated questionnaire the EORTC-QLQ-BR23/C30.

The primary objective of the current study is to evaluate the differences in long-term outcomes in HRQoL between immediate and delayed breast reconstruction, as well as to identify patient-reported differences between autologous and implant-based procedures in long-term.

Methods

Study design and protocol

The Swedish Breast Reconstruction Outcome Study (SweBRO study) was designed to assess the nationwide distribution of postmastectomy breast reconstruction. Its primary objective is to examine variations in patient well-being and quality of life across different demographic groups. Unukovych et al.13 presented the first part, SweBRO 1, which explored the demographics and patterns across Sweden. In the second part of the study Gümüscü et al. focused on analysing the differences between two distinct groups of mastectomy alone versus mastectomy and breast reconstruction6. The present third part provides subgroup analyses to identify potential differences in patient well-being associated with reconstruction methods and timing of breast reconstruction.

Study population and setting

The survey was conducted between 20 April 2016 and 22 September 2016 in Sweden. The study population consisted of women who had been diagnosed with breast cancer and had undergone a mastectomy in the years 2000, 2005 or 2010. The selection of these specific years allowed for the assessment of patients at 5, 10 and 15 years after their mastectomy procedures. To ensure comprehensive coverage, the study utilized data from the National Breast Cancer Registry, with a 99% coverage rate8. The National Cause of Death Registry was cross-referenced to exclude deceased individuals from the potential study participants.

Clinical data collection

Data regarding tumour characteristics and treatment details, including surgical interventions, chemotherapy, radiotherapy and endocrine treatment, were retrieved from the National Breast Cancer Registry. In addition to clinical data, the survey included self-reported information on sociodemographic characteristics, healthcare services availed and the type of breast reconstructive surgery pursued by the patients. Breast reconstruction information was based entirely on patient reports 5, 10 or 15 years after mastectomy. The timing was defined as ‘immediate’ if the patient reported that mastectomy and reconstruction were done simultaneously, and was defined as ‘delayed’ otherwise. Patients reported their reconstruction to be either ‘implant-based’, ‘autologous’ or a combination of those.

Invitation letters were sent out to all identified individuals. The survey was designed to offer participants the choice to respond either on paper or online, with all survey questions provided in Swedish. The survey process was previously described in detail13 ensuring that all relevant aspects were adequately addressed.

Patient-reported outcome measurements

The survey included validated PROMs to assess the participants’ health-related quality of life and well-being. The specific PROMs used in this study were the BREAST-Q and the EORTC QLQ-BRECON23 reconstruction postoperative module questionnaires. Both questionnaires are widely used in clinical research and enable the collection of standardized and meaningful data from breast cancer patients operated with mastectomy and reconstruction. By incorporating patient perspectives and experiences, these questionnaires contribute to advancing medical knowledge and refining breast cancer treatment protocols, ultimately leading to better patient outcomes and HRQoL7.

EORTC QLQ-BRECON23 was developed by the European Organization for Research and Treatment of Cancer group to assess the specific impact of breast reconstruction after mastectomy8 covering aspects such as appearance, emotional well-being, satisfaction with the reconstructive process and the impact on daily life. The validated Swedish version was used in this study9.

BREAST-Q is a prevalent and validated PROM questionnaire designed to assess the quality of life and patient satisfaction related to various aspects of breast surgery and breast-related treatments10,11. Developed by a group at the Memorial Sloan Kettering Cancer Center, this questionnaire evaluates physical, psychosocial and sexual well-being following breast surgery focusing on breast appearance, satisfaction with the surgical outcome, impact on daily activities and emotional well-being. The Swedish version of Breast Q version 1.0 was used in the current study.

Ethical approval

The study was approved by the regional ethics committee, Uppsala University (Dnr 2014/354 and Dnr 2014:354/1).

Statistical analysis

Descriptive statistics for the study cohort and distribution of missing data have previously been reported13. Statistical hypothesis testing was done comparing survey responses by groups defined according to self-reported breast reconstruction status (immediate versus delayed and autologous versus implant-based). Due to the ordinal nature of the PROM scores and observed non-normality in their distribution, all comparisons were based on the Wilcoxon rank sum test of equal distribution between reconstructed and non-reconstructed women. No causality claims are made and reported values of P are only interpreted as indicating differences between the observed distributions of study data. The overall type I error (alpha) was controlled using an unweighted Bonferroni approach and was set to 0.05, split equally across four clusters defined by questionnaires: EORTC QLQ-C30, EORTC QLQ-BR23, EORTC QLQ-BRECON23 and BREAST-Q reconstruction postoperative module (Fig. S1). Of these, the current study focuses on the BRECON23 and BREAST-Q. Each questionnaire contains several domains and higher scores mean better HRQoL or higher satisfaction (in the BREAST-Q), and higher scores mean better higher satisfaction/functioning or worse symptoms (in the QLQ-BRECON23) (Table S1). Findings were analysed overall and in 16 prespecified subgroups, defined by demographics and baseline characteristics. Due to the alpha split, questionnaires with more domains to test had more stringent limits for statistical significance in each hypothesis test (lower P for statistical significance). The limit for statistical significance was hence set to P < 0.000040849 for BRECON23 and P < 0.000036764 for BREAST-Q. All tests were two-sided and R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyses.

Results

A total of 5853 women were eligible for inclusion in the study; 1259, 1976 and 2618 from years 2000, 2005 and 2010 respectively. In total, 2904 (50%) women responded to the questionnaires and of these 895 (31%) reported having undergone breast reconstruction (BR); of whom 176 of 895 (20%) women stated to have undergone immediate and 719 of 895 (80%) delayed BR (Table 1).

Table 1 From SweBRO 1

	Total (n)	Responded	Did not respond	P	
Women	5853 (100)	2904 (100)	2949 (100)		
Selection year*				0.001	
 2000	1259 (22)	593 (20)	666 (23)		
 2005	1976 (34)	943 (32)	1033 (35)		
 2010	2618 (45)	1368 (47)	1250 (42)		
Region of residence				<0.001	
 Stockholm-Gotland	1109 (19)	591 (20)	518 (18)		
 Uppsala-Örebro	1084 (19)	578 (20)	506 (17)		
 Southeast	677 (12)	343 (12)	334 (11)		
 South	1511 (26)	732 (25)	779 (26)		
 West	1097 (19)	476 (16)	621 (21)		
 North	375 (6)	184 (6)	191 (6)		
Age at selection, years				<0.001	
 Median (i.q.r.)	57 (49–65)	49 (44–56)	60 (53–68)		
 <50	795 (27)	451 (50)	344 (17)		
 50–59	893 (31)	309 (35)	584 (29)		
 60–69	811 (28)	120 (13)	691 (34)		
 >69	405 (14)	15 (2)	390 (19)		
Age at survey, years				<0.001	
 Median (i.q.r.)	69 (60–78)	67 (58–74)	73 (62–82)		
 <50	412 (7)	221 (8)	191 (6)		
 50–59	996 (17)	583 (20)	413 (14)		
 60–69	1524 (26)	908 (31)	616 (21)		
 >69	2921 (50)	1192 (41)	1729 (59)		
Mastectomy side				0.4	
 Right	2797 (48)	1368 (47)	1429 (48)		
 Left	2970 (51)	1497 (52)	1473 (50)		
 Bilateral	86 (1)	39 (1)	47 (2)		
T stage				<0.001	
 T0/Tis	778 (13)	423 (15)	355 (12)		
 T1	1732 (30)	901 (31)	831 (28)		
 T2	1889 (32)	910 (31)	979 (33)		
 T3	340 (6)	175 (6)	165 (6)		
 T4	63 (1)	21 (1)	42 (1)		
 Tx/Missing data	1051 (18)	474 (16)	577 (20)		
N stage				<0.001	
 N0	3053 (52)	1576 (54)	1477 (50)		
 N+	856 (15)	460 (16)	396 (13)		
 Nx/Missing data	1944 (33)	868 (30)	1076 (36)		
M stage				0.002	
 Mx/M0	5120 (87)	2585 (89)	2535 (86)		
 M1	17 (0)	7 (0)	10 (0)		
 Missing data	716 (12)	312 (11)	404 (14)		
Neoadjuvant therapy				0.004	
 No neoadjuvant therapy	4593 (78)	2306 (79)	2287 (78)		
 Received neoadjuvant therapy	330 (6)	179 (6)	151 (5)		
 Missing data (pre-INCA in ‘Södra’)	930 (16)	419 (14)	511 (17)		
Postoperative radiotherapy				<0.001	
 No postoperative radiotherapy	3864 (66)	1815 (62)	2049 (69)		
 Received postoperative radiotherapy	1989 (34)	1089 (38)	900 (31)		
Postoperative endocrine therapy				0.3	
 No postoperative endocrine therapy	3261 (56)	1637 (56)	1624 (55)		
 Received postoperative endocrine therapy	2592 (44)	1267 (44)	1325 (45)		
Postoperative chemotherapy				<0.001	
 No postoperative chemotherapy	4391 (75)	2057 (71)	2334 (79)		
 Received postoperative chemotherapy	1462 (25)	847 (29)	615 (21)		
Baseline characteristics and demographics of all women.

*Selection was done on year of diagnosis in all regions except for the ‘South’ region in which women were selected based on year of mastectomy.

Regarding reconstruction type, 516 (58%) stated being reconstructed with implants and 281 (31%) with autologous tissue. In 20 (2%) women a combination of techniques had been used and in 78 (9%) the technique was not reported.

Immediate versus delayed breast reconstruction

The timing of breast reconstruction did not correlate with the PROM by either EORTC QLQ-BRECON23 or the BREAST-Q. In a single subgroup analysis of patients with no lymph node metastases (N0), the satisfaction with nipples was higher in women with delayed reconstruction compared to immediate, mean 57 versus 45.

Autologous versus implant-based BR

EORTC QLQ-BRECON23

Overall (n = 797), women with autologous reconstruction were more satisfied with surgery (71 versus 58; 13 points difference) and reported higher levels of satisfaction with their breasts (63 versus 47; 16 points) (Table 2). These differences remained significant in favour of autologous reconstruction regardless of timepoints (years 2000, 2005, 2010), patient age (<50 and ≥50 years), radiotherapy (RT+ and RT–), chemotherapy (CT+ and CT–) and endocrine therapy (ET+ and ET–) (Table 2). The largest differences were seen in the subgroup among those operated in 2000, that is 15 years after mastectomy at the time of survey. The satisfaction with breast was 66 versus 42 (difference of 24 points) and satisfaction with surgery 75 versus 54 (21 points). Among patients who had been treated with radiotherapy (RT+), satisfaction with breast (70 versus 55; 25 points difference) and satisfaction with surgery (64 versus 45; 21 points) were also in favour of autologous reconstruction. The same pattern was seen for those with tumour stage T2–T4 where radiotherapy was regarded as a potential confounding factor (Table 2).

Table 2 BREAST-Q reconstruction postop module scores by breast reconstruction modality, only showing scales and subgroups with statistically significant differences between implant-based and autologous breast reconstruction

	Total	Implant-based	Autologous	P	
All women, n	797	516	281		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	794 (100)	514 (100)	280 (100)		
 Mean(s.d.)	59(18)	56(16)	67(18)	<0.000036764	
BREAST-Q postop: Satisfaction with surgeon					
 Available (%)	790 (99)	511 (99)	279 (99)		
 Mean(s.d.)	82(20)	80(21)	87(18)	<0.000036764	
Subset: selected 2000, n	153	104	49		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	153 (100)	104 (100)	49 (100)		
 Mean(s.d.)	57(18)	52(18)	67(16)	<0.000036764	
Subset: selected 2005, n	252	164	88		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	249 (99)	162 (99)	87 (99)		
 Mean(s.d.)	59(18)	54(16)	67(18)	<0.000036764	
Subset: selected 2010, n	392	248	144		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	392 (100)	248 (100)	144 (100)		
 Mean(s.d.)	61(17)	58(16)	66(18)	<0.000036764	
Subset: age <50 years at selection, n	411	255	156		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	411 (100)	255 (100)	156 (100)		
 Mean(s.d.)	60(17)	56(14)	67(18)	<0.000036764	
Subset: age ≥50 years at selection, n	386	261	125		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	383 (99)	259 (99)	124 (99)		
 Mean(s.d.)	59(19)	55(18)	66(18)	<0.000036764	
Subset: T2–T4, n	319	182	137		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	318 (100)	181 (99)	137 (100)		
 Mean(s.d.)	60(19)	54(18)	68(18)	<0.000036764	
Subset: N0, n	480	341	139		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	479 (100)	340 (100)	139 (100)		
 Mean(s.d.)	59(18)	56(16)	65(19)	<0.000036764	
BREAST-Q postop: Satisfaction with surgeon					
 Available (%)	476 (99)	337 (99)	139 (100)		
 Mean(s.d.)	81(20)	79(20)	88(16)	<0.000036764	
Subset: RT–, n	501	397	104		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	499 (100)	396 (100)	103 (99)		
 Mean(s.d.)	58(17)	56(16)	66(19)	<0.000036764	
Subset: RT+, n	296	119	177		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	295 (100)	118 (99)	177 (100)		
 Mean(s.d.)	62(18)	54(17)	67(17)	<0.000036764	
Subset: ET–, n	467	324	143		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	465 (100)	323 (100)	142 (99)		
 Mean(s.d.)	59(18)	55(16)	66(19)	<0.000036764	
Subset: ET+, n	330	192	138		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	329 (100)	191 (99)	138 (100)		
 Mean(s.d.)	60(18)	56(17)	67(17)	<0.000036764	
Subset: CT−, n	523	373	150		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	522 (100)	373 (100)	149 (99)		
 Mean(s.d.)	58(17)	55(16)	65(18)	<0.000036764	
Subset: CT+, n	274	143	131		
BREAST-Q postop: Satisfaction with breasts					
 Available (%)	272 (99)	141 (99)	131 (100)		
 Mean(s.d.)	63(18)	58(17)	68(18)	<0.000036764	
In all BREAST-Q scales, higher scores are better. The survey was administered in 2015–2016, either 15 years (women selected in 2000), 10 years (women selected in 2005) or 5 years (women selected in 2010) after mastectomy. P are based on Wilcoxon rank sum test and are only calculated if there are at least three unique values in each group. Due to the Bonferroni adjustment, only P  < 0.000036764 are considered significant. CT, chemotherapy; ET, endocrine therapy; RT, radiotherapy.

BREAST-Q

BREAST-Q results for the whole study population also showed a higher level of satisfaction with breasts (67 versus 56; 11 points) and satisfaction with surgery (87 versus 80; 7 points) for those operated with autologous reconstruction (Table 3). The satisfaction with breasts remained significantly higher for autologous reconstruction at all time points (patients operated in 2000, 2005, 2010), regardless of patient age (<50 and ≥50 years), given radiotherapy (RT+ and RT−), chemotherapy (CT+ and CT−) and endocrine therapy (ET+ and ET−) (Table 3).

Table 3 QLQ-BRECON23 scores by breast reconstruction modality, only showing domains and subgroups with statistically significant differences between implant-based and autologous breast reconstruction

	Total	Implant-based	Autologous	P	
All women, n	797	516	281		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	787 (99)	510 (99)	277 (99)		
 Mean(s.d.)	53(28)	47(27)	63(27)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	743 (93)	476 (92)	267 (95)		
 Mean(s.d.)	63(26)	58(26)	71(25)	<0.000040849	
Subset: selected 2000, n	153	104	49		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	150 (98)	102 (98)	48 (98)		
 Mean(s.d.)	49(29)	42(28)	66(24)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	144 (94)	96 (92)	48 (98)		
 Mean(s.d.)	61(29)	54(29)	75(23)	<0.000040849	
Subset: selected 2005, n	252	164	88		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	246 (98)	161 (98)	85 (97)		
 Mean(s.d.)	51(28)	45(27)	62(28)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	232 (92)	150 (91)	82 (93)		
 Mean(s.d.)	61(27)	56(26)	71(26)	<0.000040849	
Subset: selected 2010, n	392	248	144		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	391 (100)	247 (100)	144 (100)		
 Mean(s.d.)	55(27)	50(26)	64(28)	<0.000040849	
QLQ-BRECON23: Treatment side effects					
 Available (%)	389 (99)	246 (99)	143 (99)		
 Mean(s.d.)	11(19)	8(16)	17(23)	<0.000040849	
Subset: age <50 years at selection, n	411	255	156		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	410 (100)	254 (100)	156 (100)		
 Mean(s.d.)	54(26)	48(25)	64(26)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	383 (93)	234 (92)	149 (96)		
 Mean(s.d.)	64(24)	59(23)	71(25)	<0.000040849	
Subset: age ≥50 years at selection, n	386	261	125		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	377 (98)	256 (98)	121 (97)		
 Mean(s.d.)	51(30)	46(29)	62(29)	<0.000040849	
Subset: T2–T4, n	319	182	137		
Q LQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	315 (99)	179 (98)	136 (99)		
 Mean(s.d.)	53(29)	44(28)	66(26)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	291 (91)	161 (88)	130 (95)		
 Mean(s.d.)	62(28)	54(28)	72(24)	<0.000040849	
Subset: N0, n	480	341	139		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	475 (99)	337 (99)	138 (99)		
 Mean(s.d.)	53(28)	48(27)	64(28)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	446 (93)	315 (92)	131 (94)		
 Mean(s.d.)	63(27)	59(26)	70(26)	<0.000040849	
QLQ-BRECON23: Treatment side effects					
 Available (%)	476 (99)	339 (99)	137 (99)		
 Mean(s.d.)	9(18)	6(13)	17(24)	<0.000040849	
Subset: RT–, n	501	397	104		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	497 (99)	393 (99)	104 (100)		
 Mean(s.d.)	51(28)	47(27)	63(30)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	467 (93)	368 (93)	99 (95)		
 Mean(s.d.)	62(27)	59(26)	71(27)	<0.000040849	
Subset: RT+, n	296	119	177		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	290 (98)	117 (98)	173 (98)		
 Mean(s.d.)	56(27)	45(26)	64(26)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	276 (93)	108 (91)	168 (95)		
 Mean(s.d.)	64(26)	55(27)	70(24)	<0.000040849	
Subset: ET–, n	467	324	143		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	461 (99)	321 (99)	140 (98)		
 Mean(s.d.)	51(28)	47(27)	61(29)	<0.000040849	
Subset: ET+, n	330	192	138		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	326 (99)	189 (98)	137 (99)		
 Mean(s.d.)	55(28)	47(27)	66(26)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	309 (94)	177 (92)	132 (96)		
 Mean(s.d.)	65(27)	59(27)	72(24)	<0.000040849	
Subset: CT–, n	523	373	150		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	519 (99)	370 (99)	149 (99)		
 Mean(s.d.)	50(28)	45(27)	61(28)	<0.000040849	
QLQ-BRECON23: Satisfaction with surgery					
 Available (%)	488 (93)	344 (92)	144 (96)		
 Mean(s.d.)	61(27)	57(27)	69(26)	<0.000040849	
Subset: CT+, n	274	143	131		
QLQ-BRECON23: Satisfaction with breast cosmetic					
 Available (%)	268 (98)	140 (98)	128 (98)		
 Mean(s.d.)	58(28)	51(27)	66(26)	<0.000040849	
In functional and satisfaction scales of the QLQ-BRECON23, higher scores are better. In symptom scales of the QLQ-BRECON23, lower scores are better. The survey was administered in 2015–2016, either 15 years (women selected in 2000), 10 years (women selected in 2005) or 5 years (women selected in 2010) after mastectomy. P are based on Wilcoxon rank sum test and are only calculated if there are at least three unique values in each group. Due to the Bonferroni adjustment, only P < 0.000040849 are considered significant. CT, chemotherapy; ET, endocrine therapy.

Consistently with BRECON23, the BREAST-Q reported satisfaction with breast after autologous reconstruction was higher in the subset of year 2000 (67 versus 52; difference of 15 points), among those receiving radiotherapy (RT+; 67 versus 54; 13 points), and those with larger tumour (T2–T4) subset (68 versus 54; 14 points).

Discussion

Breast reconstruction plays a crucial role in restoring physical appearance and enhancing the HRQoL following breast cancer. The reported timing of reconstruction in the current nationwide study was 20% immediate and 80% delayed due to differences in local routines and traditions, as well as availability of plastic surgeons in the six Swedish regions. The oncologic treatment priority at the time of mastectomy may also have played a role13. The current study could not identify an impact of reconstruction timing on patient-reported outcomes 5, 10 or 15 years after mastectomy.

Previous research comparing immediate versus delayed reconstruction is heterogeneous and methodologically limited. A review article by Heimes et al.4 summarizes that IBR might have a positive impact on patients’ well-being. The majority of the analysed studies, however, showed that psychosocial outcomes did not differ between the groups of mastectomy alone, IBR and DBR.

A recent population based-cohort study in England with a follow-up time of 12 years14 reported that women with abdominal flap BR reported higher levels of satisfaction with breasts than other BR groups (that is, expander/implant, latissimus dorsi flap).

In a larger multicentre prospective study of 1639 immediate and 147 delayed reconstruction patients from 11 hospitals in the USA and Canada by Yoon et al.15, no significant differences were seen in patient satisfaction or in psychosocial, sexual or physical well-being at a 2-year follow-up survey. This is in line with our study that validates and extrapolates these findings to a long-term perspective (5–15 years).

In the current study, delayed reconstruction was associated with higher levels of satisfaction with nipples compared to immediate reconstruction. This observation could be explained by the fact that patients undergoing delayed reconstruction had experienced a period without nipples and consequently they may exhibit a more positive attitude towards nipple reconstruction. In contrast, in cases of nipple-sparing immediate reconstructions, patients retain a reference memory of their native nipples.

Comparing autologous to implant-based breast reconstructions, the autologous methods, which use the patient’s own tissue, were associated with fewer breast symptoms and higher satisfaction scores as in earlier studies6,14–16. This confirms that autologous reconstruction may offer more natural-looking and feeling breasts, contributing to improved well-being. Same pattern was seen in the subgroup analyses based on time passed since mastectomy, satisfaction with breasts was higher in the autologous group compared with the implant-based group both in the BRECON23 and BREAST-Q surveys.

A review by Eltahir et al.16 found, similarly to the current study, that autologous breast reconstruction outperformed implant-based reconstruction in satisfaction with breasts and physical well-being. A similar pattern was observed in a meta-analysis by Toyserkani et al17.

The findings of the current study may guide healthcare professionals in tailoring the treatment plans and enhance overall care for breast cancer patients. As described in a study by Frost et al.18, informed decision-making is of importance to women and will affect satisfaction with outcome, as women reported less satisfaction with information they received about different reconstructions methods and timing of reconstruction.

Our study encompassed the entire eligible population of a country and was assessed over a period of 5, 10 and 15 years. This renders the study particularly relevant as it provides insights into long-term outcomes on a national level including diverse demographics. By including a comprehensive population, using validated questionnaires and conducting analyses for clinically relevant subgroups, and a long follow-up period, the study contributes valuable information that can enhance the understanding for HRQoL after breast reconstruction.

The current study carries certain limitations. The retrospective design of the survey years after the surgery lead to data collection limitations. The generalizability may be limited and the findings may not fully apply outside of Sweden in countries with a different population and different healthcare settings. Like in any comparative study on breast reconstruction, a selection bias in reconstruction timing and methods for reconstruction may have occurred. Self-reported questionnaires may be subject to recall or information biases and inaccuracies. Advances in surgical techniques over time, for example reconstructions in 2005 versus 2015, may also influence patient-reported outcomes.

In addition to identifying statistically significant differences between groups, which was done in this study using a conservative Bonferroni approach, it is also important to consider whether differences are clinically significant. If a group difference is not statistically significant, we cannot be certain that any observed difference is not due to random chance. and it is of course inappropriate to discuss whether they are clinically relevant. On the other hand, a statistically significant difference is not necessarily clinically relevant or meaningful to patients. No estimates of what is meaningful to patients are available for the scores in the BREAST-Q or QLQ-BRECON23 and, as no appropriate anchors were available in this data set, such thresholds could not be derived in this study.

This Swedish long-term follow-up survey highlights the importance of breast reconstruction for well-being and quality of life postmastectomy. Across various demographic and treatment subgroups, women undergoing autologous reconstruction consistently reported higher levels of satisfaction with both surgical outcomes and breast appearance. Yet no significant impact of reconstruction timing on the outcomes was observed 5–15 years postmastectomy. These findings provide valuable insights for clinicians and patients, facilitating informed decision-making to optimize outcomes and the quality of care for women undergoing mastectomy.

Supplementary Material

znae240_Supplementary_Data

Author contributions

Rojda Gümüscü (Writing—original draft), Fredrik Wärnberg (Writing—review & editing), Jana de Boniface (Writing—review & editing), Malin Sund (Writing—review & editing), Kristina Ahsberg (Writing—review & editing), Emma Hansson (Writing—review & editing), Folke Folkvaljon (CRediT contribution not specified), Dmytro Unukovych (Writing—review & editing), and Maria Mani (Supervision, Writing—review & editing)

Funding

The study was funded by ALF (Agreement on Medical Education and Research) grants and The Swedish Breast Cancer Association.

This is an original article and the manuscript has not been submitted earlier.

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS online.

Data availability

The data supporting findings of this study are available upon reasonable request from the corresponding author.
==== Refs
References

1 Howes  BH, Watson  DI, Xu  C, Fosh  B, Canepa  M, Dean  NR. Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: a case-controlled cohort study. J Plast Reconstr Aesthet Surg  2016;69 :1184–1191 27406255
2 Zhong  T, Hu  J, Bagher  S, Vo  A, O'Neill  AC, Butler  K  et al  A comparison of psychological response, body image, sexuality, and quality of life between immediate and delayed autologous tissue breast reconstruction: a prospective long-term outcome study. Plast Reconstr Surg  2016;138 :772–780 27673514
3 Al-Ghazal  SK, Sully  L, Fallowfield  L, Blamey  RW. The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol  2000;26 :17–19 10718173
4 Heimes  AS, Stewen  K, Hasenburg  A. Psychosocial aspects of immediate versus delayed breast reconstruction. Breast Care (Basel)  2017;12 :374–377 29456468
5 Harcourt  D, Rumsey  N. Psychological aspects of breast reconstruction: a review of the literature. J Adv Nurs  2001;35 :477–487 11529946
6 Gümüscü  R, Unukovych  D, Wärnberg  F, de Boniface  J, Sund  M, Åhsberg  K  et al  National long-term patient-reported outcomes following mastectomy with or without breast reconstruction: the Swedish breast reconstruction outcome study part 2 (SweBRO 2). BJS Open  2024;8 :zrae003 38415759
7 Weick  L, Brorson  F, Jepsen  C, Lidén  M, Jensen  EW, Hansson  E. Giving meaning to patient reported outcomes in breast reconstruction after mastectomy—a systematic review of available scores and suggestions for further research. Breast  2022;61 :91–97 34929423
8 Davies  CF, Macefield  R, Avery  K, Blazeby  JM, Potter  S. Patient-reported outcome measures for post-mastectomy breast reconstruction: a systematic review of development and measurement properties. Ann Surg Oncol  2021;28 :386–404 32602063
9 Winters  ZE, Afzal  M, Rutherford  C, Holzner  B, Rumpold  G, da Costa Vieira  RA  et al  International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction. Br J Surg  2018;105 :209–222 29116657
10 Pusic  AL, Klassen  AF, Scott  AM, Klok  JA, Cordeiro  PG, Cano  SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg  2009;124 :345–353 19644246
11 Seth  I, Seth  N, Bulloch  G, Rozen  WM, Hunter-Smith  DJ. Systematic review of BREAST-Q: a tool to evaluate post-mastectomy breast reconstruction. Breast Cancer  2021;13 :711–724 34938118
12 Phan  R, Hunter-Smith  DJ, Rozen  WM. The use of patient reported outcome measures in assessing patient outcomes when comparing autologous to alloplastic breast reconstruction: a systematic review. Gland Surg  2019;8 :452–460 31538071
13 Unukovych  D, Gümüscü  R, Wärnberg  F, de Boniface  J, Eriksen  C, Sund  M  et al  Breast reconstruction patterns from a Swedish nation-wide survey. Eur J Surg Oncol  2020;46 :1867–1873 32698944
14 Johnson  L, White  P, Jeevan  R, Browne  J, Gulliver-Clarke  C, O'Donoghue  J  et al  Long-term patient-reported outcomes of immediate breast reconstruction after mastectomy for breast cancer: population-based cohort study. Br J Surg  2023;110 :1815–1823 37766501
15 Yoon  AP, Qi  J, Brown  DL, Kim  HM, Hamill  JB, Erdmann-Sager  J  et al  Outcomes of immediate versus delayed breast reconstruction: results of a multicenter prospective study. Breast  2018;37 :72–79 29102781
16 Eltahir  Y, Krabbe-Timmerman  IS, Sadok  N, Werker  PMN, de Bock  GH. Outcome of quality of life for women undergoing autologous versus alloplastic breast reconstruction following mastectomy: a systematic review and meta-analysis. Plast Reconstr Surg  2020;145 :1109–1123 32332522
17 Toyserkani  NM, Jørgensen  MG, Tabatabaeifar  S, Damsgaard  T, Sørensen  JA. Autologous versus implant-based breast reconstruction: a systematic review and meta-analysis of BREAST-Q patient-reported outcomes. J Plast Reconstr Aesthet Surg  2020;73 :278–285 31711862
18 Frost  MH, Slezak  JM, Tran  NV, Williams  CI, Johnson  JL, Woods  JE  et al  Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol  2005;23 :7849–7856 16204003
